Menu
Back to User profile » Prof. Dr. Klaus Rabe
Papers published by Prof. Dr. Klaus Rabe:
Characteristics of Current Smokers versus Former Smokers with COPD and Their Associations with Smoking Cessation Within 4.5 Years: Results from COSYCONET
Alter P, Stoleriu C, Kahnert K, Henke MO, Bals R, Trudzinski FC, Watz H, Speicher T, Söhler S, Welte T, Rabe KF, Wouters EFM, Vogelmeier CF, Jörres RA
International Journal of Chronic Obstructive Pulmonary Disease 2023, 18:2911-2923
Published Date: 6 December 2023
Dupilumab Efficacy in Patients with Uncontrolled Moderate-to-Severe Type 2 Asthma Regardless of Perennial Aeroallergen Sensitization
Corren J, Jackson DJ, Casale TB, Borish L, Rabe KF, Busse WW, Maspero JF, Jackson DJ, Daizadeh N, Altincatal A, Radwan A, Khodzhayev A, Djandji M, Jacob-Nara JA, Rowe PJ, Deniz Y
Journal of Asthma and Allergy 2023, 16:249-260
Published Date: 7 March 2023
Benefits of Budesonide/Glycopyrronium/Formoterol Fumarate Dihydrate on COPD Exacerbations, Lung Function, Symptoms, and Quality of Life Across Blood Eosinophil Ranges: A Post-Hoc Analysis of Data from ETHOS
Bafadhel M, Rabe KF, Martinez FJ, Singh D, Darken P, Jenkins M, Aurivillius M, Patel M, Dorinsky P
International Journal of Chronic Obstructive Pulmonary Disease 2022, 17:3061-3073
Published Date: 6 December 2022
Disease Progression and Age as Factors Underlying Multimorbidity in Patients with COPD: Results from COSYCONET
Alter P, Kahnert K, Trudzinski FC, Bals R, Watz H, Speicher T, Söhler S, Andreas S, Welte T, Rabe KF, Wouters EFM, Sassmann-Schweda A, Wirtz H, Ficker JH, Vogelmeier CF, Jörres RA
International Journal of Chronic Obstructive Pulmonary Disease 2022, 17:1703-1713
Published Date: 29 July 2022
Association of Airway Eosinophilia with Small Airway Dysfunction in Patients with Mild and at Risk for COPD
Abdo M, Pedersen F, Trinkmann F, Herth FJF, Rabe KF, Kirsten AM, Watz H
International Journal of Chronic Obstructive Pulmonary Disease 2022, 17:1403-1408
Published Date: 17 June 2022
The Relevance of Small Airway Dysfunction in Asthma with Nocturnal Symptoms
Abdo M, Trinkmann F, Kirsten AM, Biller H, Pedersen F, Waschki B, Von Mutius E, Kopp M, Hansen G, Rabe KF, Bahmer T, Watz H
Journal of Asthma and Allergy 2021, 14:897-905
Published Date: 13 July 2021
Persistent Uncontrolled Asthma: Long-Term Impact on Physical Activity and Body Composition
Abdo M, Waschki B, Kirsten AM, Trinkmann F, Biller H, Herzmann C, von Mutius E, Kopp M, Hansen G, Rabe KF, Bahmer T, Watz H
Journal of Asthma and Allergy 2021, 14:229-240
Published Date: 12 March 2021
Influence of Cell Quality on Inflammatory Biomarkers in COPD Sputum Supernatant
Pedersen F, Trinkmann F, Abdo M, Kirsten AM, Rabe KF, Watz H, Baraldo S, Saetta M, Hohlfeld JM, Holz O
International Journal of Chronic Obstructive Pulmonary Disease 2021, 16:487-493
Published Date: 1 March 2021
Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Improves Lung Function versus Monotherapies in GOLD Category A Patients with COPD: Pooled Data from the Phase III PINNACLE Studies
Martinez FJ, Rabe KF, Lipworth BJ, Arora S, Jenkins M, Martin UJ, Reisner C
International Journal of Chronic Obstructive Pulmonary Disease 2020, 15:99-106
Published Date: 9 January 2020
Long-Term Safety and Efficacy of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Formulated Using Co-Suspension Delivery Technology in Japanese Patients with COPD
Ichinose M, Fukushima Y, Inoue Y, Hataji O, Ferguson GT, Rabe KF, Hayashi N, Okada H, Takikawa M, Bourne E, Ballal S, DeAngelis K, Aurivillius M, Reisner C, Dorinsky P
International Journal of Chronic Obstructive Pulmonary Disease 2019, 14:2993-3002
Published Date: 23 December 2019
Efficacy and Safety of Budesonide/Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Formulated Using Co-Suspension Delivery Technology in Japanese Patients with COPD: A Subgroup Analysis of the KRONOS Study
Ichinose M, Fukushima Y, Inoue Y, Hataji O, Ferguson GT, Rabe KF, Hayashi N, Okada H, Takikawa M, Bourne E, Ballal S, DeAngelis K, Aurivillius M, Dorinsky P, Reisner C
International Journal of Chronic Obstructive Pulmonary Disease 2019, 14:2979-2991
Published Date: 23 December 2019
Rating sputum cell quality in clinical trials for asthma and COPD treatment
Pedersen F, Zissler UM, Watz H, Rabe KF, Hohlfeld JM, Holz O
International Journal of Chronic Obstructive Pulmonary Disease 2019, 14:195-198
Published Date: 8 January 2019
Influence of body mass on predicted values of static hyperinflation in COPD
Alter P, Rabe KF, Schulz H, Vogelmeier CF, Jörres RA
International Journal of Chronic Obstructive Pulmonary Disease 2018, 13:2551-2555
Published Date: 23 August 2018
Identification of novel target genes in human lung tissue involved in chronic obstructive pulmonary disease
Heinbockel L, Marwitz S, Schromm AB, Watz H, Kugler C, Ammerpohl O, Schnepf K, Rabe KF, Droemann D, Goldmann T
International Journal of Chronic Obstructive Pulmonary Disease 2018, 13:2255-2259
Published Date: 26 July 2018
Use of a 4-week up-titration regimen of roflumilast in patients with severe COPD
Watz H, Bagul N, Rabe KF, Rennard S, Alagappan VKT, Román J, Facius A, Calverley PMA
International Journal of Chronic Obstructive Pulmonary Disease 2018, 13:813-822
Published Date: 6 March 2018
Plasminogen activator inhibitor-1 is elevated in patients with COPD independent of metabolic and cardiovascular function
Waschki B, Watz H, Holz O, Magnussen H, Olejnicka B, Welte T, Rabe KF, Janciauskiene S
International Journal of Chronic Obstructive Pulmonary Disease 2017, 12:981-987
Published Date: 22 March 2017
Roflumilast: a review of its use in the treatment of COPD
Wedzicha JA, Calverley PMA, Rabe KF
International Journal of Chronic Obstructive Pulmonary Disease 2016, 11:81-90
Published Date: 6 January 2016